Volume 11, Issue 4 (9-2021)                   Iran J Ped Hematol Oncol 2021, 11(4): 270-279 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Yazdanparast A, Fathpour G, Saberianpour S. Cardiovascular involvement in blood cancers: ALL, AML, CLL, and CML. Iran J Ped Hematol Oncol 2021; 11 (4) :270-279
URL: http://ijpho.ssu.ac.ir/article-1-662-en.html
Vascular and Endovascular Surgery Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
Abstract:   (952 Views)
Global cancer statistics will continue to grow in the coming years. Leukemia is the fifth leading cause of death in the world and the second one in Iran; therefore, it is very important to study the affected areas, including the cardiovascular system in this disease. In heart cancer, tumors whose primary origin is the heart are called primary tumors, which are very rare. Tumors that originate in other parts of the body and spread to the heart are called secondary tumors. Although heart cancer is still rare, most cancers found in the heart come from other parts of the body and are considered as secondary tumors. The symptoms of metastatic heart cancer vary and depend on the location and extent of the lesion. Cancer can also affect the heart in other ways. One of these ways is the effect of the treatments used, which is reported among acute lymphocytic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, and chronic myelogenous leukemia due to the use of tyrosine kinase inhibitors as the main drug in reducing mortality among these patients. Pericardial involvement is reported to be the most common cardiovascular complication of drug use among different kinds of leukemias. In this article, we try to collect cardiovascular evidence related to acute lymphocytic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, and chronic myelogenous leukemia, separately.
Full-Text [PDF 619 kb]   (661 Downloads)    
Subject: Heart
Received: 2021/05/27 | Accepted: 2021/08/23 | Published: 2021/09/19

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Iranian Journal of Pediatric Hematology and Oncology

Designed & Developed by : Yektaweb